Sustainability & Climate

Cerro de Pasco Resources locks in a vital community deal in Peru, a key step in a $400M plan to turn a century of mining waste into a profitable venture.

Beyond the factory, China's manufacturers are now tech pioneers. The MEI Awards reveal a strategic shift that is reshaping global markets and supply chains.

A new FDA clearance for its AI software enhances Hyperfine's portable MRI, positioning it to disrupt the lucrative stroke diagnostics market. Here's why.

As Spruce Biosciences preps its rare disease drug for FDA review, the addition of a commercial veteran signals a high-stakes shift from R&D to market.

NAVEE launches its rugged XT5 Pro scooter, challenging off-road rivals with a blend of high-performance tech, certified safety, and eco-friendly power.

With a dual listing on Brazil's B3 exchange, DeFi Technologies isn't just expanding—it's building a strategic blueprint for institutional crypto adoption.

As Natuzzi prepares its Q3 results, the luxury furniture maker's costly bet on Italian craftsmanship faces a critical test amid a tough economy.

A new drug for a leading cause of blindness missed its primary goal, yet its unique ability to improve vision offers new hope for millions of patients.

Natera's legal retreat solidifies a major victory for NeoGenomics, clearing the runway for its RaDaR ST launch and shaking the diagnostic patent landscape.

A pivotal trial success in lupus for BTK inhibitor orelabrutinib not only offers new hope for patients but also validates Zenas BioPharma's strategy.

As New Jersey's cannabis market booms, Grown Rogue's one-year success reveals a potent strategy for blending craft quality with low-cost execution.

Beyond software, a new accelerator offers hardware startups a rare advantage, bridging the gap from university labs to investor-ready prototypes.

BIEL Crystal's award-winning 'Witch Cloak' coating is more than just durable glass; it’s a leap forward in securing the physical gateway to our digital lives.

TPG RE Finance Trust declared a steady $0.24 dividend. We analyze if this signals portfolio resilience or a strategic play in a volatile market.

Your health plan is evolving beyond medical bills. Insurers are now funding doulas, food, and transport to tackle the root causes of poor health.

Updated trial results for Lilly's Inluriyo-Verzenio combo extend life without chemo, positioning the firm for dominance in a competitive oncology market.

Global crypto exchange HTX gains a crucial regulatory nod in Pakistan, paving the way for licensed operations in one of the world's fastest-growing digital asset hubs.

A novel drug for alcohol use disorder gets key scientific backing. It promises the benefits of psychedelics with fewer risks, shaking up a $35B market.

Sintana Energy's all-share acquisition of Challenger gets final approval, creating a new exploration leader with high-impact assets in Namibia and Uruguay.

Aligos Therapeutics is using strategic stock grants to lure top talent. Is this a savvy growth play or a creeping cost for shareholders? We break it down.